Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Lymphoma, Mantle-Cell × axicabtagene ciloleucel × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, Large B-Cell, Diffuse 16 Lymphoma, Non-Hodgkin 6 Lymphoma, Follicular 6 Lymphoma, B-Cell 4 Lymphoma 4 Recurrence 3 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Hematologic Neoplasms 2 Neurotoxicity Syndromes 1 Lymphoma, Mantle-Cell 1 Lymphoma, B-Cell, Marginal Zone 1 HIV Infections 1 Disease Progression 1 Dendritic Cell Sarcoma, Interdigitating 1 Cytokine Release Syndrome 1

Interventions

Rituximab 201 Cyclophosphamide 184 fludarabine phosphate 94 Peripheral Blood Stem Cell Transplantation 88 Filgrastim 78 Etoposide 66 Cytarabine 62 ibrutinib 60 Mycophenolic Acid 60 Cyclosporine 58 Bortezomib 58 Whole-Body Irradiation 57 Lenalidomide 53 Bendamustine Hydrochloride 53 Vincristine 50 Radiotherapy 50 Melphalan 49 fludarabine 48 Doxorubicin 45 Methotrexate 42 Tacrolimus 40 Busulfan 39 Prednisone 37 Dexamethasone 36 Antilymphocyte Serum 36 Carmustine 33 venetoclax 28 Granulocyte Colony-Stimulating Factor 27 acalabrutinib 25 zanubrutinib 24

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02601313 2026-03-18

ZUMA-2

Gilead Sciences

Phase 2 Completed

105 enrolled 33 charts 2 FDA

Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡